[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fakih IVF Fertility Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,77,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100648763","phase-2-efficacy-of-recombinant-human-g-csf-in-women-with-unexplained-recurrent-miscarriage-100648763",false,"NCT07724405","Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage","A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer","GEM","Inclusion:\n\n1. Women aged 18-44 years\n2. ≥2 unexplained pregnancy losses\n3. Undergoing IVF with PGT-A tested embryos\n4. BMI 19-35 kg\u002Fm² 6.\n\nExclusion:\n\n1. Parental karyotype abnormalities\n2. Correctable uterine abnormalities\n3. Systemic autoimmune disease \u002F thrombophilia\n4. Uncontrolled systemic illness (e.g. diabetes, infection)\n5. Previous G-CSF therapy\n6. Hypersensitivity to rhG-CSF or E. coli proteins\n7. HIV, malignancy within 5 years, or severe cardiovascular\u002Frespiratory history","FEMALE","18 Years","44 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.\n\nOne leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.\n\nThis study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.\n\nEarlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.",[28,29],"Recurrent Pregnancy Loss","Recurrent Miscarriages",[31,32,33,34,35,36],"T helper cells","Immunological causes of miscarriage","miscarriage","pregnancy loss","granulocyte-colony stimulating factor","G-CSF","RECRUITING","2026-07-20",{"date":40,"type":41},"2026-07-24","ACTUAL",{"date":43,"type":41},"2026-07-10",{"date":45,"type":22},"2027-10-10",{"name":47,"class":48},"Fakih IVF Fertility Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":49},"100645392","an-investigation-of-the-effect-of-vitamin-d-level-during-frozen-embryo-transfer-fet-in-ivf-and-pregnancy-outcomes-100645392","NCT07681115","An Investigation of the Effect of Vitamin D Level During Frozen Embryo Transfer (FET) in IVF and Pregnancy Outcomes","Vitamin D Levels and Pregnancy Outcomes Following Frozen Embryo Transfer (FET) in the UAE","VitD in FET","Inclusion:\n\n* Women undergoing frozen embryo transfer (FET) at Fakih IVF.\n* Age between 18 and 40 years.\n* Body mass index (BMI) between 18 and 40 kg\u002Fm².\n* Patients who had serum vitamin D levels assessed within three months prior to FET\n* Supplementation with Vitamin D if deficient \\\u003C 30 ng\u002FmL (75 nmol\u002FL).\n\nExclusion:\n\n* Age below 18 years or above 40 years.\n* BMI below 18 kg\u002Fm² or above 40 kg\u002Fm².\n* Patients who did not have vitamin D levels measured within three months prior to FET.\n* Patients who were found to have low vitamin D levels but did not receive supplementation.\n* Patients with recurrent implantation failure (RIF).\n* Patients with known uterine factors affecting implantation (e.g., congenital uterine anomalies, intrauterine adhesions, submucosal fibroids).\n* Patients with significant medical comorbidities that may affect pregnancy outcomes.","40 Years",{"count":60,"type":22},126,"OBSERVATIONAL","Vitamin D is best known for keeping our bones healthy, but growing research suggests it may also play a role in fertility. Many In vitro fertilization (IVF) clinics now routinely check vitamin D levels and prescribe supplements before treatment, but the science is still unclear on whether this actually improves the chances of pregnancy.\n\nOur study, based in the United Arab Emirates (UAE), aims to find out whether a woman's vitamin D level on the day of her frozen embryo transfer (FET) makes a difference to whether she becomes pregnant and delivers a baby. The UAE is an ideal setting for this research, as vitamin D deficiency is particularly common in the region. The findings could shape how fertility clinics screen and treat women seeking fertility treatment in the future.",[64,65],"Vitamin D Insufficiency","In Vitro Fertilization and Embryo Transfer",[67,68],"frozen embryo transfer cycle","Vitamin D","2026-07-13",{"date":71,"type":41},"2026-07-15",{"date":73,"type":41},"2026-06-01",{"date":75,"type":22},"2027-08",{"name":47,"class":48},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":102},"100646863","assessing-the-correlation-between-phospholipase-c-zeta-measurements-and-semen-parameters-100646863","NCT07684339","Assessing the Correlation Between Phospholipase C Zeta Measurements and Semen Parameters","Assessing the Correlation Between Phospholipase C Zeta (PLCZeta) Measurements and Semen Parameters","PLCZeta","Couple inclusion criteria:\n\n* Presenting to the IVF clinic for IVF\u002FICSI treatment or routine semen analysis\n* Semen sample must have a total sperm count of ≥1 million sperm\u002Fml\n* Availability of excess, leftover sperm after clinical treatment procedures\n* Couples must have experienced infertility for at least one year and be undergoing fertility treatment\n* Undergoing standard clinical treatment protocols (including embryo culture and, when applicable, PGTA) with routinely collected treatment outcome data\n* Sufficient ovarian reserve and\u002For meeting the clinic's standard criteria for fertility treatment\n\nCouple exclusion criteria:\n\n* Known genetic disorders affecting fertility\n* History of vasectomy or other irreversible sterilization procedures\n* Current use of medications known to affect sperm parameters (e.g., exogenous androgens, chemotherapeutic agents, or other drugs specifically impacting spermatogenesis)\n* Recent history of chemotherapy or radiation therapy\n* Female age \\>38 years old\n* Known chromosomal abnormalities or genetic disorders that directly affect oocyte quality or embryo development\n* Presence of severe uterine or pelvic pathology (e.g., significant uterine anomalies, advanced endometriosis)\n* Documented ovarian failure or extremely diminished ovarian reserve as determined by AMH levels (AMH \\>1 ng\u002FmL, AFC ≥5)\n* Use of medications or undergoing treatments that could significantly alter oocyte quality or embryogenesis (outside standard ART protocols).","MALE",{"count":87,"type":22},200,"With declining fertility rates Worldwide, Assisted Reproductive Technology is seen as a viable solution for infertility, however, individual success rates following ART remain relatively low, rarely exceeding \\~50%. The European Society for Human Reproduction and Embryology (ESHRE) indicates pregnancy rates per embryo transfer remain below 50%. Additionally, male infertility is regarded as a leading contributor to global infertility with approximately a third of cases attributed to genetic causes while half of the cases remain unexplained.\n\nIn this observational study we investigate the correlation between phospholipase C Zeta (PLCζ ) measurements and semen parameters. PLCζ is a sperm-specific protein which is introduced into a mature egg (oocyte) following gamete fusion and upon introduction, PLCζ is believed to initiate a series of characteristic calcium ion oscillations which lead to oocyte activation and persist beyond the completion of meiosis.\n\nMounting evidence implicates defects in PLCζ in cases of male factor infertility where intracytoplasmic sperm injection (ICSI; whereby a single sperm is injected into the oocyte) is unsuccessful. Furthermore, defects in PLCζ are also increasingly implicated in cases of male sub-fertility, which affects a much larger proportion of the global population. Numerous studies now indicate that PLCζ not only holds significant value as a therapeutic to rescue cases of ICSI failure, but also as a prognostic diagnostic test of male fertility. Indeed, the reduction or absence of normal PLCζ within sperm has been linked to cases of male factor infertility in humans, either due to inactivation through mutation, due to abrogation of protein levels in sperm as a result of mutation in the PLCζ promoter, or mutations within coding exonic regions of the PLCζ gene. Such data indicate both therapeutic, and diagnostic applications for PLCζ within the fertility clinic. This study seeks to determine the effect of abnormal PLCζ on semen parameters and correlate that with downstream events including clinical pregnancy and live birth rates.",[90,91],"Male Infertility","Male Subfertility",[93,94,90],"PLCζ","phospholipase C Zeta","2026-06-29",{"date":97,"type":41},"2026-07-06",{"date":99,"type":22},"2026-07-01",{"date":75,"type":22},{"name":47,"class":48},2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":49},"100645036","phase-2-thymosin-1-for-recurrent-implantation-failure-100645036","NCT07675980","Thymosin-α1 for Recurrent Implantation Failure","Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial","Thy-α1 for RIF","Inclusion Criteria:\n\n1. -Women 18-40 years\n2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos\n3. \\- Normal parental karyotypes\n4. \\- Normal uterine cavity on imaging\n5. \\- Negative antiphospholipid panel\n6. \\- Thyroid and prolactin controlled within local reference standards\n\nExclusion Criteria:\n\n1. Identified\u002Fcorrectable non-immune cause of RPL (chromosomal, anatomic, endocrine)\n2. \\- Active malignancy\n3. -Active infection\n4. \\- Uncontrolled systemic disease\n5. \\- Current systemic immunosuppression",{"count":112,"type":22},136,[25,114],"PHASE3","Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF\u002FICSI cycles.",[117],"Recurrent Implantation Faliure",[119,120,121,122],"Thymosin","recurrent implantation failure","Thymosin alpha","PGT-a tested embryos",{"date":124,"type":41},"2026-06-30",{"date":126,"type":41},"2026-02-11",{"date":128,"type":22},"2027-06",{"name":47,"class":48},""]